Biosimilars - Market Insights, Competitive Landscape, and Market Forecast - 2034

Biosimilar Market Summary

Overview:

• The Biosimilar market is estimated at USD 34.50 billion in 2025 and is projected to reach USD 134.30 billion by 2034. Growth is anchored in the wave of high-value biologic patent expirations, expanding regulatory pathways and interchangeability, and the global push to lower healthcare costs and widen patient access.
• The global Biosimilar market is growing at a CAGR of 16.3% during the forecast period from 2026 to 2034.
• By product, the monoclonal antibodies segment dominated the Biosimilar market with a 58% share in 2025.
• By indication, the oncology segment dominated the Biosimilar market with a 34% share in 2025.
• By manufacturing type, the in-house manufacturing segment dominated the Biosimilar market with a 64% share in 2025.
• By distribution channel, the hospital pharmacies segment dominated the Biosimilar market with a 56% share in 2025.
• North America dominated the global Biosimilar market revenue with a 44% share in 2025, representing the highest regional market share globally.

Biosimilar are biological products that are highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, purity, and potency. Unlike small-molecule generics, biosimilar are large, complex proteins produced in living cell systems, including monoclonal antibodies, fusion proteins, erythropoietins, granulocyte colony-stimulating factors, insulins, and growth hormones. Approval follows dedicated regulatory pathways, the Biologics Price Competition and Innovation Act in the United States and the European Medicines Agency framework, and relies on a totality-of-evidence approach combining extensive analytical characterization, non-clinical studies, and confirmatory clinical trials. The biosimilar ecosystem spans cell-line engineering, large-scale biomanufacturing, regulatory approval, distribution, and payer-driven adoption across hospital and retail channels. Major applications include oncology, autoimmune and inflammatory diseases, diabetes, blood disorders, and ophthalmology. Since the first European biosimilar approval in 2006 and the first United States approval in 2015, the market has matured rapidly, with the United States Food and Drug Administration having approved 96 biosimilar by the end of 2025, transforming biosimilar from a nascent category into a central pillar of sustainable, cost-effective biologic therapy.

Biosimilar Market Key Growth Drivers

• A wave of high-value biologic patent expirations, including Humira, Stelara, Eylea, and Prolia, is opening multi-billion-dollar markets to biosimilar competition and accelerating new launches.
• Biosimilar deliver substantial cost savings, with oncology biosimilar priced at 50% to 70% below reference average sales prices and denosumab biosimilar launched at discounts above 80%, and Cardinal Health projecting up to USD 181 billion in future United States healthcare savings.
• The rising global burden of cancer, autoimmune disease, and diabetes is expanding demand for affordable biologic therapy, with the International Agency for Research on Cancer projecting cancer cases to rise from 20 million in 2022 to 35 million by 2050.
• Maturing regulatory frameworks and the expansion of interchangeability designations, with 25 of the 96 United States biosimilar approved as interchangeable by the end of 2025, are improving pharmacy-level substitution and adoption.
• The FDA's modernization of the biosimilar pathway, prioritizing advanced analytical data over repetitive clinical trials, is lowering development costs and accelerating new entrants.
• Expanding manufacturing capacity in Asia-Pacific and vertically integrated supply chains are lowering production costs and broadening global access.
• The convergence of patent cliffs, payer cost-containment pressure, and a maturing developer ecosystem is expected to sustain strong double-digit growth in the global Biosimilar market through 2034.

Key Companies in Biosimilar Market

The competitive landscape is led by the following active manufacturers and developers:

• Sandoz Group AG
• Amgen Inc.
• Pfizer Inc.
• Celltrion, Inc.
• Samsung Bioepis Co., Ltd.
• Biocon Biologics Ltd.
• Boehringer Ingelheim International GmbH
• Fresenius Kabi AG
• Teva Pharmaceutical Industries Ltd.
• Organon & Co.

Factors Contributing to the Growth of the Biosimilar Market

Market Drivers

Wave of High-Value Biologic Patent Expirations Opening Large Markets

The single most powerful driver of the Biosimilar market is the cascade of patent expirations on blockbuster biologics. The loss of exclusivity for adalimumab (Humira), once the world's best-selling drug, opened the United States market to multiple biosimilar from 2023, followed by ustekinumab (Stelara), aflibercept (Eylea), and denosumab (Prolia and Xgeva). As of October 2025, annual United States sales for Prolia and Xgeva alone reached USD 5.3 billion, illustrating the scale of the markets now exposed to competition. Each expiration converts a protected, high-priced franchise into a contested market in which biosimilar rapidly capture share. With major checkpoint inhibitors such as pembrolizumab (Keytruda) and nivolumab (Opdivo) approaching patent loss toward 2028, the pipeline of addressable biologics continues to expand, sustaining new launches and revenue growth through 2034. Source: United States Food and Drug Administration; company disclosures, 2023-2026.

Substantial Cost Savings and Payer-Driven Adoption

Biosimilar are central to healthcare cost containment, which underpins strong policy and payer support. Oncology biosimilar referencing trastuzumab, bevacizumab, and rituximab carry average sales price discounts of 50% to 70%, while denosumab biosimilar launched with wholesale acquisition cost discounts above 80%, and pegfilgrastim's average sales price has fallen by 95% since biosimilar entry. Cardinal Health has projected that, under supportive market and policy conditions, biosimilar could deliver up to USD 181 billion in future savings for the United States healthcare system. Payers, pharmacy benefit managers, and national health systems are increasingly steering utilization toward biosimilar through formulary preference and substitution, exemplified by CVS Caremark's decision to favor Stelara biosimilar. These savings dynamics make biosimilar adoption a structural priority for health systems worldwide.

Market Restraints

Despite strong momentum, the Biosimilar market faces material constraints. Regulatory complexity remains significant, as biosimilar development requires extensive analytical characterization, comparative studies, and navigation of distinct FDA, European Medicines Agency, and national frameworks, lengthening and raising the cost of development, which has historically reached USD 100 million to USD 300 million per program. Manufacturing is capital intensive and technically demanding, requiring specialized bioreactor capacity, cold-chain logistics, and rigorous quality control that create high barriers to entry and supply-chain risk. Commercial adoption is impeded by intellectual-property litigation, originator pricing strategies, and patent-thicket defenses that delay launches even after approval, with a substantial share of approved biosimilar remaining uncommercialized. Reimbursement and access are further complicated by pharmacy benefit manager rebate practices and formulary incentives that can favor higher-priced originators, distorting competition and limiting savings, concerns raised in United States Congressional testimony. Reimbursement remains uneven across geographies, and physician and patient confidence in switching, while improving, still requires education. A persistent biosimilar gap is also emerging, as only a small proportion of biologics expected to lose exclusivity over the next decade currently have biosimilar in development, reflecting the high cost and uncertain returns of pursuing complex molecules. Together, these regulatory, manufacturing, supply-chain, reimbursement, and adoption barriers temper the pace of growth across the forecast period, even as the underlying drivers remain firmly intact.

Biosimilar Market Segment Analysis

The Biosimilar Market by Product (Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte Colony-Stimulating Factor, Growth Hormone, Fusion Proteins, Anticoagulants, Others), Indication (Oncology, Autoimmune and Inflammatory Diseases, Blood Disorders, Diabetes, Growth Hormone Deficiency, Ophthalmology, Others), Manufacturing Type (In-house Manufacturing, Contract Manufacturing), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Specialty and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Rest of World).

By Product

Dominant Subsegment: Monoclonal Antibodies. The monoclonal antibodies category is expected to dominate the market.

Dominant: Monoclonal Antibodies ~ 58%

The monoclonal antibodies segment accounted for 58% of the Biosimilar market in 2025. Monoclonal antibodies are the leading product class because the highest-value reference biologics losing exclusivity, including adalimumab, trastuzumab, infliximab, rituximab, bevacizumab, ustekinumab, and denosumab, are monoclonal antibodies. These molecules anchor multi-billion-dollar franchises across oncology and immunology, and their biosimilar capture large markets quickly once launched. The segment's dominance is reinforced by a deep pipeline and a steady cadence of approvals: the FDA cleared multiple ustekinumab biosimilar referencing Stelara, denosumab biosimilar referencing Prolia and Xgeva, aflibercept biosimilar such as Celltrion's Eydenzelt, the first omalizumab biosimilar Omlyclo, and the first golimumab biosimilar in 2026. Antibody biosimilar also command the largest absolute savings, with oncology antibodies discounted 50% to 70% versus reference average sales prices. Continued investment in antibody manufacturing capacity by Celltrion, Samsung Bioepis, Amgen, and Biocon Biologics, together with the approaching patent cliffs for pembrolizumab and nivolumab, secures the segment's leadership across the forecast period, while insulins, erythropoietins, colony-stimulating factors, growth hormones, and fusion proteins occupy established but smaller positions.

By Indication

Dominant Subsegment: Oncology. The oncology category is expected to dominate the market.

Dominant: Oncology ~ 34%

The oncology segment accounted for 34% of the Biosimilar market in 2025. Oncology is the leading indication because cancer biologics represent some of the largest and most expensive therapeutic franchises, and biosimilar competition delivers substantial savings in a setting of rising disease burden. The International Agency for Research on Cancer recorded 20 million new cancer cases in 2022 and projects 35 million by 2050, expanding the treated population. Biosimilar referencing trastuzumab, bevacizumab, rituximab, and pertuzumab are widely used across breast, colorectal, lung, and hematologic cancers, with average sales price discounts of 50% to 70% improving access and freeing budget for novel therapies. Supportive-care biosimilar, including pegfilgrastim and filgrastim for chemotherapy-induced neutropenia and denosumab for cancer-related bone disease, further deepen oncology demand, and the FDA approval of Shanghai Henlius Biotech's interchangeable pertuzumab biosimilar Poherdy in 2025 illustrates continued expansion. The approaching loss of exclusivity for checkpoint inhibitors such as pembrolizumab and nivolumab toward 2028 promises a second major wave of oncology biosimilar. These dynamics secure oncology's leadership, while autoimmune and inflammatory diseases follow closely as a major indication.

Biosimilar Market Region Analysis

Dominant Region: North America

North America accounted for 44% of the global Biosimilar market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects the high price of reference biologics in the United States, which makes biosimilar savings especially large, together with a maturing regulatory environment and an accelerating wave of launches. The Biologics Price Competition and Innovation Act established the United States approval pathway, and by the end of 2025 the FDA had approved 96 biosimilar, 25 of them interchangeable, with 18 approvals in 2025 alone across oncology, immunology, endocrinology, and ophthalmology. The launch of adalimumab, ustekinumab, denosumab, and aflibercept biosimilar has unlocked very large markets, with Prolia and Xgeva alone representing USD 5.3 billion in annual United States sales. Payer and pharmacy-benefit-manager steering, exemplified by formulary decisions favoring Stelara biosimilar, is converting approvals into volume. Strong disease burden, a deep developer base, and FDA pathway modernization that lowers development cost anchor the region's continued leadership.

Dominant: North America ~ 44% (Largest)

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Biosimilar market. The region's elevated CAGR is driven by large patient populations, rising biologic demand, and rapidly expanding low-cost manufacturing capacity across China, India, South Korea, and Japan. Domestic leaders including Celltrion, Samsung Bioepis, Biocon Biologics, and Shanghai Henlius Biotech are scaling production and exporting globally, while government initiatives promote affordable biologics and domestic biomanufacturing. Recent activity underscores the momentum, including Biocon Biologics' launch of the etanercept biosimilar Nepexto in Australia and Samsung Bioepis' domestic partnership with Boryung for a denosumab biosimilar in 2025. Growing local demand, supportive industrial policy, and the region's role as a global production hub position Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 44% of the global Biosimilar market revenue in 2025. The United States dominates on the strength of high reference-biologic prices, a maturing FDA pathway with expanding interchangeability, and an accelerating launch cadence across oncology, immunology, and bone health, while Canada contributes through provincial biosimilar switching policies that have driven rapid uptake.

Europe

Europe is a large and pioneering biosimilar market, having approved the first biosimilar in 2006 through the European Medicines Agency and achieved the highest adoption maturity through national tenders and switching programs in Germany, the United Kingdom, France, and the Nordics. Continued approvals, including Biocon Biologics' MHRA clearance of denosumab biosimilar Vevzuo and Evfraxy in 2025, sustain European leadership in volume and clinical acceptance.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by large patient populations, expanding manufacturing capacity, and supportive government policy across China, India, South Korea, and Japan. Regional leaders such as Celltrion, Samsung Bioepis, Biocon Biologics, and Shanghai Henlius Biotech serve both domestic demand and global export markets, accelerating access to affordable biologics.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Rising chronic disease burden, improving regulatory capacity, and access initiatives such as Sandoz's Act4Biosimilar are expanding availability, while local partnerships and tenders gradually broaden the use of lower-cost biologic therapies.

Biosimilar Market Competitive Landscape

The Biosimilar market is classified as Moderately Concentrated. A group of global pharmaceutical and specialized biosimilar developers holds the majority of revenue, with Sandoz, Amgen, and Pfizer leveraging regulatory expertise and established distribution, and Asian leaders Celltrion, Samsung Bioepis, and Biocon Biologics driving cost-effective large-scale production. A widening field of generic manufacturers and specialized developers competes across individual molecules, increasing fragmentation in newer categories such as denosumab and ustekinumab.

The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Moderately concentrated, with a few global leaders alongside many molecule-specific entrants and rising competition in newly opened markets.
• Leading players: Sandoz, Amgen, Pfizer, Celltrion, Samsung Bioepis, and Biocon Biologics anchor the top tier.
• Geographic reach: Leaders operate global commercial networks across North America and Europe, with Asia-Pacific developers expanding rapidly into Western and emerging markets.
• Product portfolio strength: Top players hold broad portfolios spanning oncology, immunology, endocrinology, and ophthalmology biosimilar.
• Pipeline strength: Deep pipelines targeting upcoming patent cliffs, including pembrolizumab, nivolumab, and high-dose aflibercept.
• Strategic partnerships: Extensive licensing, co-development, and commercialization deals, such as Samsung Bioepis with Organon and Bio-Thera with Hikma and Accord.
• M&A activity: Consolidation continues, including Biocon's acquisition of the Viatris biosimilar business and generic-maker entries by Amneal and Sun.
• Manufacturing capabilities: Large vertically integrated biomanufacturing and contract capacity are key competitive moats and supply-chain advantages.
• Innovation focus: High-concentration and citrate-free formulations, autoinjector and on-body delivery, interchangeability, and analytical-data-led development.

Biosimilar Market Recent Developmental Activities

In May 2026, Bio-Thera Solutions, Ltd. (with Accord BioPharma, Inc.), received FDA approval for Immgolis and Immgolis Intri (golimumab-sldi), the first golimumab biosimilar in the United States, approved as interchangeable to Simponi and Simponi Aria for rheumatoid arthritis and ulcerative colitis. Strategic significance: Opens the anti-TNF golimumab market and expands interchangeable options in immunology.

In December 2025, Amneal Pharmaceuticals, Inc. (with mAbxience), received FDA approval for Boncresa and Oziltus (denosumab-mobz), referencing Prolia and Xgeva, concluding a year in which eight pairs of denosumab biosimilar were approved. Strategic significance: Intensifies competition in a USD 5.3 billion reference market and signals deeper participation by generic manufacturers.

Biosimilar Market Segmentation

Biosimilar Market by Product

• Monoclonal Antibodies
• Insulin
• Erythropoietin
• Granulocyte Colony-Stimulating Factor
• Growth Hormone
• Fusion Proteins
• Anticoagulants
• Others

Biosimilar Market by Indication

• Oncology
• Autoimmune and Inflammatory Diseases
• Blood Disorders
• Diabetes
• Growth Hormone Deficiency
• Ophthalmology
• Others

Biosimilar Market by Manufacturing Type

• In-house Manufacturing
• Contract Manufacturing

Biosimilar Market by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Specialty and Online Pharmacies

Biosimilar Market by Geography

• North America Biosimilar Market
• United States Biosimilar Market Size in USD million (2023-2034)
• Canada Biosimilar Market Size in USD million (2023-2034)
• Mexico Biosimilar Market Size in USD million (2023-2034)
• Europe Biosimilar Market
• Germany Biosimilar Market Size in USD million (2023-2034)
• United Kingdom Biosimilar Market Size in USD million (2023-2034)
• France Biosimilar Market Size in USD million (2023-2034)
• Italy Biosimilar Market Size in USD million (2023-2034)
• Spain Biosimilar Market Size in USD million (2023-2034)
• Rest of Europe Biosimilar Market Size in USD million (2023-2034)
• Asia-Pacific Biosimilar Market
• China Biosimilar Market Size in USD million (2023-2034)
• Japan Biosimilar Market Size in USD million (2023-2034)
• India Biosimilar Market Size in USD million (2023-2034)
• Australia Biosimilar Market Size in USD million (2023-2034)
• South Korea Biosimilar Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Biosimilar Market Size in USD million (2023-2034)
• Rest of the World (RoW) Biosimilar Market
• Middle East Biosimilar Market Size in USD million (2023-2034)
• Africa Biosimilar Market Size in USD million (2023-2034)
• South America Biosimilar Market Size in USD million (2023-2034)

Key Takeaways from the Biosimilar Market Report Study

• Market size analysis for the current biosimilar market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global biosimilar market.
• Various opportunities available for competitors in the biosimilar market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current biosimilar market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for biosimilar market growth in the future?

Target audience who can benefit from this biosimilar market report study

• Biosimilar product providers
• Research organizations and consulting companies
• Biosimilar-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in biosimilar
• Various end-users who want to know more about the biosimilar market and the latest technological developments in the biosimilar market.

Frequently Asked Questions:

Q1. What is the growth rate of the Biosimilar market?

The Biosimilar market is projected to expand at a CAGR of 16.3% during the forecast period from 2026-2034.

Q2. What is the market size of the Biosimilar market?

The Biosimilar market is estimated at USD 34.50 billion in 2025 and is projected to reach USD 134.30 billion by 2034.

Q3. Which region dominates the Biosimilar market?

North America dominated the Biosimilar market with a 44% share of global revenue in 2025, supported by high reference-biologic prices that maximize biosimilar savings, a maturing FDA pathway with expanding interchangeability, and an accelerating launch cadence across oncology, immunology, and bone health. Europe remains the most mature adoption market, while Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Biosimilar market?

The principal drivers are the wave of high-value biologic patent expirations, including Humira, Stelara, Eylea, and Prolia; substantial cost savings, with oncology biosimilar discounted 50% to 70% and Cardinal Health projecting up to USD 181 billion in future United States savings; the rising global burden of cancer, autoimmune disease, and diabetes; and maturing regulatory pathways, with the FDA having approved 96 biosimilar including 25 interchangeable products by the end of 2025.

Q5. Who are the major players in the Biosimilar market?

The major players include Sandoz Group AG, Amgen Inc., Pfizer Inc., Celltrion, Inc., Samsung Bioepis Co., Ltd., Biocon Biologics Ltd., Boehringer Ingelheim International GmbH, Fresenius Kabi AG, Teva Pharmaceutical Industries Ltd., and Organon & Co., among other active manufacturers profiled in the Competitive Landscape section. Sandoz, Amgen, and Pfizer lead on regulatory expertise and distribution, while Celltrion, Samsung Bioepis, and Biocon Biologics drive cost-effective large-scale production.